Article Detail

Home > Article Detail
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

Determination of Liraglutide in Rat Plasma Using Selective Liquid Chromatography–Tandem Mass Spectrometry

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2023, v.14 no.4, pp.141-146
https://doi.org/10.5478/MSL.2023.14.4.141
Kim Younah (Kyungpook National University)
Jo Hyoje (Kyungpook National University)
Lee Yelim (Dongkook Pharmaceutical)
Kang Soo Yeon (Dongkook Pharmaceutical)
Lee Sangkyu (Sungkyunkwan University)
Supplimentary material
  • Downloaded
  • Viewed

Abstract

Liraglutide is a medication prescribed for the management of type 2 diabetes and chronic obesity. A simple, sensi- tive, and selective liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantitative analysis of liraglutide in rat plasma. After a simple protein precipitation step, liraglutide was chromatographically separated using the ACQUITY Premier Peptide BEH C18 Column with mobile phases comprising 50% acetonitrile and 50% methanol, and water with 0.3% FA. Positive ion electrospray ionization in multiple reaction monitoring mode was used to achieve detection. Good linearity was observed in the 5–600 ng/mL concentration range (R 2 > 0.99). Liraglutide had intra- and inter-day precision values of 2.13%–9.86% and 4.14%–8.36%, respectively. The accuracy ranged from −2.36% to 2.58%. The recovery and matrix effect were within acceptable limits. This selective LC-MS/MS method was used to study the pharmacoki- netic properties of liraglutide after subcutaneous administration in rats.

keywords
liraglutide, LC-MS/MS, rat, pharmacokinetics, carryover


Submission Date
2023-10-07
Revised Date
2023-11-07
Accepted Date
2023-11-09
상단으로 이동

Mass Spectrometry Letters